PMA device
Enteryx Procedure Kit
Boston Scientific Corp · Agent, Bulking, Injectable For Gastro-Urology Use (LNM, Class III) · First FDA decision May 26, 2004, newest Jun 2, 2005Overactive bladder and urinary incontinence
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
0
Naming "Enteryx Procedure"
MAUDE reports
2
Brand "Enteryx Procedure", since 2015
PubMed studies
6
Mentioning "Enteryx Procedure"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Enteryx Procedure Kit
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- ENTERYX PROCEDURE KITPMA supplement
P020006-S008 · Decided Jun 2, 2005 · 143 days after receipt · Normal 180 Day Track No User Fee
Device type: AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE (LNM) · GI, Urology & Nephrology
- ENTERYX PROCEDURE KITPMA supplement
P020006-S004 · Decided May 26, 2004 · 47 days after receipt · Normal 180 Day Track No User Fee
Device type: AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE (LNM) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Enteryx Procedure", any status and sponsor, newest update first.
No registered device study names "Enteryx Procedure".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Enteryx Procedure", and for the whole product code for context.
This brand
2 reports: 0 malfunction, 2 injury, 0 death
Whole product code LNM
544 reports: 170 malfunction, 369 injury, 2 death
Newest reports for this brand
- ENTERYX PROCEDURE KITInjury
3005099803-2023-03572 · Received Jun 30, 2023 · Event dated Jan 1, 2004
Device type: Agent, Bulking, Injectable For Gastro-Urology Use (LNM)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Insufficient Information
- ENTERYX PROCEDURE KITInjury
BOSTON SCIENTIFIC - MARLBOROUGH
3005099803-2016-00024 · Received Jan 6, 2016
Device type: Agent, Bulking, Injectable For Gastro-Urology Use (LNM)
Device problem as coded: Migration or Expulsion of Device
Patient problem as coded: Dysphagia/ Odynophagia; Pain
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0040-06 · Started Sep 23, 2005 · Posted by FDA Oct 28, 2005
Reason given: Incorrect implantation may cause serious health complications
Cause as FDA categorized it: Other · Device type: Agent, Bulking, Injectable For Gastro-Urology Use (LNM)
Published research
The most relevant PubMed records for "Enteryx Procedure"[tiab]. The summary above synthesizes these.
- Enteryx Implant for Gastroesophageal Reflux Disease.
Johnson DA · Curr Treat Options Gastroenterol · 2005
- Enteryx for gastroesophageal reflux disease.
Johnson DA · Expert Rev Med Devices · 2005Review
- Accurate localization of tissue layers in the esophagus by using a double-lumen injection catheter: implications for the Enteryx procedure.
Ganz RA, Rydell M, Termin P · Gastrointest Endosc · 2006Research Support, Non-U.S. Gov't
- Visceral artery embolization after endoscopic injection of Enteryx for gastroesophageal reflux disease.
Helo N, Wu A, Moon E, et al. · J Radiol Case Rep · 2014Case Reports
- Pneumomediastinum following Enteryx injection for the treatment of gastroesophageal reflux disease.
Noh KW, Loeb DS, Stockland A, et al. · Am J Gastroenterol · 2005Case Reports
- New endoscopic treatments for gastroesophageal reflux disease.
Ozawa S, Yoshida M, Kumai K, et al. · Ann Thorac Cardiovasc Surg · 2005
Other devices of this type
Also filed under product code LNM.
- Deflux Injectable GelPalette Life Sciences · PMA 2016
- Macroplastique ImplantsUroplasty, LLC · PMA 2023
- Solesta (Injectable Gel)Palette Life Sciences · PMA 2021
- Durasphere Injectable Bulking AgentCarbon Medical Technologies, Inc. · PMA 2026
- Coaptite Injectable ImplantMerz North America, Inc. · PMA 2024
- Contigen Bard Collagen ImplantAllergan, Inc. · PMA 2009
- Bard Tegress Urethral ImplantC.R. Bard, Inc. · PMA 2006
- Durasphere ExpCarbon Medical Technologies, Inc. · PMA 2004
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.